Gennova in talks with government to set competitive price for mRNA vaccine

Gennova Biopharmaceuticals said its Covid-19 vaccine, which received an emergency use authorization (EUA) from India’s drug regulator on Wednesday, would be offered at a competitive price. Pune-based Gennova’s product is the first locally developed mRNA Covid vaccine. The government had partly funded the development of the vaccine. Chief operating officer Samit Mehta said pricing negotiations were underway with the government.

“In terms of pricing, this is something that is always being discussed with the government. I can definitely say that compared to global peers on this platform, we will be much more competitive,” he said. he said at a press conference.

Since Gennova got the risk manufacturing approval, it has already produced 7 million doses which have been cleared not only by the company’s internal quality control, but also by the government’s central drug nodal laboratory in Kasauli. in Himachal Pradesh, he said. “So like when the orders come in, we should be able to ship them right away.”

Mehta said the addressable market for the vaccine would be for booster shots, as a majority of the population has already received both doses of Covid vaccines. He said positioning the use of the vaccine in children would be the next thing.

“We have reported in the past that there is an Omicron variant-specific vaccine that we have already developed that could be rolled out for the booster. The next step will also involve pediatrics as this is the safest option available,” he said.

Many children have fallen ill since schools reopened, he said. “So I think these (vaccinating children) will be the next logical step.” The company plans to leverage the global presence of its parent company, Emcure Pharmaceuticals, to export the new vaccine.

Gennova has already received requests from Latin America as well as Southeast Asia, Mehta said. A Latin American country has already submitted the documents along with India’s latest EUA update with its regulatory agency, he added.

Parent company Emcure operates in more than 70 countries, he said. “The entire network has now been granted emergency use authorization, so any requests that may come in will be properly routed,” he added.

Mehta also said that a considerable sum had been spent on the development of the vaccine. The company had been working for more than four years to develop an mRNA platform, he said.


Comments are closed.